Propanc Biopharma, Inc.

Latest News

Sep 17, 2025

Propanc Biopharma Receives Certificate of Grant for “Proenzyme Composition” Patent from US Patent & Trademark Office

Fourth US Granted Patent Captures Claims for Future Clinical Dose of PRP MELBOURNE, Australia, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a…

View All Press Releases

Sep 2, 2025

Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum

Aug 25, 2025

Propanc Biopharma Provides Shareholder Update

Aug 19, 2025

Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ
Latest Publication Blocking Tumor Support from Cancer-Associated Fibroblasts in Tumor Microenvironment View All Publications
Trypsinogen and chymotrypsinogen: potent anti- tumor agents
Pancreatic (pro)enzymes treatment suppresses BXPC-3 pancreatic Cancer Stem Cell subpopulation and impairs tumour engrafting
Antitumour efficacy of chymotrypsinogen and trypsinogen